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Table 3
1yr TRM: HCT-CI Score Comparisons p-value
0 vs 1-2 0.180
1-2 vs3 0.238
3 0.706
Table 1
Grade and timing of aGVHD relative to absolute CD38 bright CD8+TEM cells/
mL prior to aGVHD onset
Patient Maximum
Absolute
CD38
Bright
CD8+ TEM
(cells/mL)
Maximum
Absolute
CD38
Bright
CD8+ TEM
(Day Post
HSCT)
Onset
of
acute
GVHD
(Day
Post
HSCT)
Onset of
CD38
Bright
CD8+ TEM
>35cells/
uL (Day
Post HSCT)
Maximum
grade of
aGVHD
Organ(s)
involved
1 64 26 33 26 1 Skin
2 69 48 58 37 3 GI
Liver
3 32 34 41 34 1 Skin
4 304 34 47 20 1 Skin
5 231 7 34 7 1 Skin
6 41 24 34 24 2 Skin
7 99 25 32 25 4 Skin
Liver
8 98 16 23 16 3 Skin
GI
9 90 52 69 17 3 Skin
Liver
10 183 37 52 20 3 Skin
GI
Liver
11 42 33 42 33 3 Skin
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Introduction: Identiﬁcation of patients at high risk for trans-
plant relatedmortality (TRM)prior to allogeneichematopoietic
cell transplantation (alloHCT) is crucial. However, the hetero-
geneity of alloHCT indications, conditioning regimens, patient
characteristics and center-speciﬁc practices makes deﬁning
generalizable risk factors for TRM a perpetual challenge. In a
retrospective study, Smith et al. (Blood, 2011) concluded that
Sorror’s 17-item pre-alloHCTadult comorbidity indexwas also
an effective tool for risk-stratifying pediatric alloHCT patients.
In this study,weattempt to re-validate theHCT-CIpublishedby
Smith et al. in a cohort of patients receiving well-deﬁned
Busulfan (Bu)-based conditioning regimens.
Methods: Retrospective cohort study of 165 patients (<22y)
who underwent alloHCT. Patients conditioned with 1 of 3
Bu-based regimens were included: reduced intensity (RIC):
Bu (6.4-8mg/kg)+ Fludarabine (Flu) (150mg/m2), reduced
toxicity (RTC): Bu (12.8-16mg/kg)+ Flu (180mg/m2) and
myeloablative (MAC): Bu (12.8-16mg/kg)+ cyclophospha-
mide (120-200mg/kg) or melphalan (135mg/m2).
Results: Median age at alloHCT was 9.5y (0.1-22y), malig-
nant group n¼102, non-malignant group n¼63. Pre-alloHCT
comorbidities were scored using HCT-CI and risk group
numbers were as follows: 32 (19.4%) group 0, 69 (41.8%)
group 1-2, 64 (38.8%) group 3. The difference in incidence
of TRM at 1y in each HCT-CI group was not statistically sig-
niﬁcant for malignant vs non-malignant patients. 1yr TRM of
patients receiving RIC, RTC and MAC regimens was also not
signiﬁcantly impacted by pre-transplant HCT-CI scores in
each of these cohorts. Data outlined in supplemental tables.
Conclusion: Preliminary results suggest that the HCT-CI as it
standsmay not be a generalizable risk stratiﬁcation tool for all
pediatric alloHCT patients. Contrary to aforementioned
studies, we were unable to demonstrate poorer outcomes in
patientswithHCT-CI score3. One potential reason could be a
smaller sample size in our study (n¼166 vs. 252).We excluded
total body irradiation as it is only used inMAC regimens at our
center which might have skewed the comparison between
RIC/RTC vs. MAC thus making ﬁndings generalizable. FurtherTable 1
HCT-CI
Score
1y TRM All Patients p-value
Number Deceased Living
0 32 9 (28.1%) 23 (71.9%) 0.299
1-2 69 19 (27.5%) 50 (72.5%)
3 64 11 (17.2%) 53 (82.8%)
All 165 39 (23.6%) 126 (76.4%)
Table 2
HCT-CI
Score
1y TRM: Conditioning Regimens p-value
RIC RTC MAC
0 16.7% (1/6) 0% (0/11) 20% (3/15) 0.376
1-2 5% (1/20) 13% (3/23) 15.4% (4/26) 0.576
3 0% (0/18) 10.7% (3/28) 11.1% (2/18) 0.576analysis is currently being conducted to identify risk factors
distinct fromtheHCT-CI thatmayhave ahigher impactonTRM
in pediatric patients undergoing alloHCT.98
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Acute graft versus host disease (aGVHD) is an important
complication of allogeneic hematopoietic stem cell trans-
plantation (HSCT). A need exists for validated biomarkersGI
12 36 11 15 11 4 Skin
GI
13 82 15 29 15 4 GI
14 37 43 44 12 2 Skin
15 151 45 79 15 3 Skin
GI
16 63 23 33 23 4 Skin
GI
17 47 25 31 25 1 Skin
18 87 17 18 17 3 GI
19 69 56 59 56 1 Skin
20 2 25 28 NA 1 Skin
21 12 36 37 NA 1 Skin
22 70 28 38 21 1 Skin
23 128 42 45 28 3 Skin
GI
Figure 1. T-cell ﬂow cytometry plots. A. Lymphocyte gating and CD8 cell gating. B. Healthy control ﬂow cytometry plot demonstrating gating strategy for CD38 bright
CD8+TEM cells. C. Representative ﬂow cytometry plot showing reduced number of CD8 events and low percent age of CCR7-CD45RA-cells and low number of CD38
bright effector memory T-cells in patients without acute graft versus host disease. D. Representative ﬂow cytometry plot showing elevated CD8 events, high per-
centage of CCR7-CD45RA-cells and high percentage of CD38 bright effector memory T-cells in patients 1-3 weeks prior to clinical acute graft versus host disease.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S79eS107S100that can effectively predict the onset of aGVHD prior to
clinical symptoms to allow for pre-emptive therapy. Expan-
sion of CD8+ effector memory T-cells (TEM) have been
observed at day +28 after HSCT in patients with aGVHD,
suggesting their role in aGVHD pathophysiology. CD38 is a
marker of T-cell activation but is also crucial for leukocyte
migration through the endothelium.We hypothesized that peripheral blood expansion of acti-
vated CD8+ TEMs would be observed following HSCT prior to
onset of aGVHD symptoms.
Peripheral venous blood was collected twice weekly
following HSCT for 7 weeks in 49 consecutive pediatric and
young adult HSCT recipients. Samples were incubated with
ﬂuorochrome-conjugated antibodies against CD45, CD3,
Figure 2A. Kinetics of average CD38 bright CD8+TEM cells/m shown twice weekly in patients who developed acute graft versus host disease and in patients who did
not develop acute graft versus host disase. *p<0.05. 2B. Receiver operating characteristic curve analysis showing area under the characteristic curve of 0.859 for
CD8+TEM cells/mL as a predictor of acute graft versus host disease. 2C. Probability of developing acute graft versus host disease in patients who demonstrate an
expansion of absolute CD38 bright CD8+TEM cells/mL to >35 versus <35.
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ﬁxation and analyzed by ﬂow cytometry on a FACS Canto II
ﬂow cytometer (BD Biosciences). Data were analyzed using
FCS Express (De Novo Software). TEM cells were deﬁned as
CD3+CD8+CCR7-CD45RA-lymphocytes (Figure 1). Patients
were followed for 100 days for development of aGVHD.
Twenty-three patients of median age 13.5 years (range 1-33
years) developed grade I-IV aGVHD at a median of 37 days
(15-79 days) after HCST (Table 1). Peripheral expansion of
CD38 bright CD8+TEM cells was observed at a median of 8
days (range 1-34 days) prior to clinical symptoms of aGVHD
(Figure 2A). A receiver-operating characteristic curve
analysis revealed an area-under the curve of 0.85 (Figure
2B). Expansion of absolute CD38 bright CD8+ TEM of >
35 cells/mL predicted aGVHD with a sensitivity of 82.6%,
speciﬁcity 91.6%, positive predictive value of 90.5% and
negative predictive value of 84.6%. The cumulative inci-
dence of aGVHD was 90% in patients with CD38
bright CD8+TEM expansion and 15% in patients without
(p<0.0001) (Figure 2C).
Expansion of CD38 bright CD8+ TEM populations is a novel
predictor of aGVHD and CD38 up regulation prior to aGVHD
onset could represent trafﬁcking lymphocytes.99
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Background: Hematopoietic stem cell transplantation
(HSCT) is curative for many non-malignant pediatric disor-
ders, including hemoglobinopathies, bone marrow failure
syndromes, and immunodeﬁciencies. There has been great
